Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19305381 | 1.00 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1HPGDTACR3 | |
| SCHEMBL20238311 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1HPGDRIPK1 | |
| SCHEMBL20238063 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1HPGDRIPK1 | |
| SCHEMBL8062915 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1HPGDRIPK1 | |
| SCHEMBL17882273 | 0.83 | RIPK1 (0.70) | KMT2AMEN1TACR3POLBRIPK1 | |
| SCHEMBL19435062 | 0.83 | RIPK1 (0.70) | KMT2AMEN1TACR3POLBRIPK1 | |
| SCHEMBL15170378 | 0.83 | KMT2A (0.53) | ALDH1A1KMT2AMEN1TACR3POLB | |
| SCHEMBL15170380 | 0.83 | KMT2A (0.53) | ALDH1A1KMT2AMEN1TACR3POLB | |
| SCHEMBL20237731 | 0.82 | ALDH1A1 (0.54) | ALDH1A1KMT2AMEN1HPGDRIPK1 | |
| SCHEMBL20238750 | 0.82 | ALDH1A1 (0.54) | ALDH1A1KMT2AMEN1HPGDRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| CN-107074887-B | Substituted dihydropyrrolopyrazoles | 宇部兴产株式会社 | 2020-12-22 | — | — | CN | disclosed |
| US-10131679-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| WO-2017188358-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| WO-2017188369-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF ATOPIC DERMATITIS | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| WO-2017188357-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR DOSING IN COMBINATION WITH OTHER PSORIASIS TREATMENT DRUG | 宇部興産株式会社 | 2017-11-02 | — | — | WO | disclosed |
| EP-3214086-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | Ube Industries, Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-3214086-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | Ube Industries, Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016068287-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | 宇部興産株式会社 | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313727-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | QDPR, CYP2D6, DCLK3 | ALDH1A1 246/4885KMT2A 2707/4885MEN1 1501/4885 |
| US-10131679-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, DCLK3 | ALDH1A1 246/4885KMT2A 2707/4885MEN1 1501/4885 |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, KCNJ11 | ALDH1A1 190/4885KMT2A 2605/4885MEN1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.